A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

February 5, 2021

Study Completion Date

February 5, 2021

Conditions
Active Non-segmental Vitiligo
Interventions
DRUG

PF-06651600

Induction dose 1. Oral tablet taken QD

DRUG

PF-06651600

Induction dose 2. Oral tablet taken QD

DRUG

PF-06651600

Maintenance dose A. Oral tablet taken QD

DRUG

PF-06651600

Maintenance Dose B. Oral tablet taken QD

DRUG

PF-06651600

Maintenance Dose C. Oral tablet taken QD

DRUG

placebo

placebo

DRUG

PF06700841

Oral tablet taken QD

DEVICE

narrow-band UVB phototherapy

Phototherapy will be combined with PF-06651600

Trial Locations (92)

1070

Hôpital Erasme Dermatology, Brussels

1090

UZ Brussel - Dermatology, Brussels

2010

The Skin Hospital, Darlinghurst

2217

Premier Specialists Pty Ltd, Kogarah

3002

Sinclair Dermatology, East Melbourne

3050

The Royal Melbourne Hospital, Parkville

3052

The Royal Melbourne Hospital, Parkville

3053

Skin Health Institute, Carlton

4102

Veracity Clinical Research Pty Ltd, Woolloongabba

9000

UZ Gent - Dermatology, Ghent

10002

National Taiwan University Hospital, Taipei

10003

Icahn School of Medicine at Mount Sinai, New York

10023

Upper West Side Dermatology c/o TrialSpark, Inc, New York

10065

MDCS: Medical Dermatology & Cosmetic Surgery (TrialSpark, Inc.), New York

10326

Dongguk University Ilsan Hospital, Goyang-si

11572

South Nassau Dermatology, Oceanside

TrialSpark, Inc. - Russell W. Cohen, MD, Oceanside

14004

Hospital Universitario Reina Sofia, Córdoba

16247

The Catholic University of Korea, St. Vincent's Hospital, Suwon

16499

Ajou University Hospital, Suwon

20815

Chevy Chase Dermatology Center (TrialSpark, Inc.), Chevy Chase

TrialSpark - Samantha Toerge, MD, Chevy Chase

20852

TrialSpark - Ronald Shore, MD, Rockville

22182

Tamjidi Skin Institute (TrialSpark, Inc.), Vienna

22332

Inha University Hospital, Incheon

23502

Virginia Clinical Research, Inc, Norfolk

23538

Universitaetsklinikum Schleswig-Holstein, Campus Luebeck CCIM, Lübeck

28034

Hospital Universitario Ramón y Cajal, Madrid

28046

Hospital Universitario La Paz, Madrid

28411

PMG Research of Wilmington, LLC, Wilmington

32073

Park Avenue Dermatology, Orange Park

33165

New Horizon Research Center, Miami

33613

ForCare Clinical Research, Tampa

43215

Remington-Davis, Inc. Clinical Research, Columbus

43220

ForeFront Dermatology, Columbus

46026

Hospital Universitari i Politecnic La Fe, Valencia

48149

Universitaetsklinikum Muenster, Münster

48202

Henry Ford Hospital Department of Dermatology, Detroit

48455

Fachklinik Bad Bentheim, Fachbereich Dermatologie und Allergologie, Dermatologische Ambulanz, Bad Bentheim

55131

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz

55455

University of Minnesota Department of Dermatology, Minneapolis

60590

Universitätsklinikum Frankfurt, Klinik für Dermatologie, Venerologie und Allergologie, Frankfurt am Main

60657

Advanced Skin and MOHS Surgery Center, c/o TrialSpark, Inc., Chicago

70403

National Cheng Kung University Hospital, Tainan City

74136

Vital Prospects Clinical Research Institute, PC, Tulsa

77030

Pickens Academic Tower, Houston

The University of Texas Health Science Center at Houston, Houston

The University of Texas MD Anderson Cancer Center, Houston

78701

University Physicians Group, Austin

83301

Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

90036

Vitiligo and Pigmentation Institute Of Southern California, Los Angeles

91054

Universitaetsklinikum Erlangen Hautklinik Studienambulanz, Erlangen

92056

Dermatology Specialists, Inc., Oceanside

92562

Dermatology Specialist, Inc., Murrieta

92647

Marvel Research, LLC, Huntington Beach

92697

University of California, Irvine, Dermatology Clinical Research Center, Irvine

95816

UC Davis Health, Sacramento

06606

Brookside Dermatology Associates, Bridgeport

New England Research Associates, LLC, Bridgeport

02111

Tobias & Battite, Inc., Boston

Tufts Medical Center, Boston

01605

UMass Memorial Medical Center, Hahnemann Campus, Worcester

01655

Investigational Drug Service Pharmacy, Worcester

UMass Memorial Medical Center Ear Nose and Throat, Worcester

University of Massachusetts Medical School, Worcester

07044

The Dermatology Group, P.C., Verona

75390-9191

University of Texas Southwestern Medical Center, Dallas

V3R 6A7

Dr. Chih-ho Hong Medical Inc., Surrey

V3V 0C6

Enverus Medical Research, Surrey

V5Z 4E8

University of British Columbia, Vancouver

R3M 3Z4

Wiseman Dermatology Research Inc., Winnipeg

L1S 7K8

CCA Medical Research, Ajax

N6A 3H7

Guenther Research Inc., London

L3P 1X3

Lynderm Research Inc., Markham

L5H 1G9

DermEdge Research, Mississauga

M2M 4J5

North York Research Inc., North York

L6J 7W5

The Centre for Clinical Trials, Oakville

L4B 1A5

The Centre for Dermatology, Richmond Hill

N2J 1C4

K.Papp Clinical Research, Waterloo

H2X 2V1

Innovaderm Research Inc., Montreal

G1V 4X7

Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ), Québec

G1W 4R4

Centre de Recherche Saint-Louis, Québec

G1W1S2

Centre de Recherche Saint-Louis, Québec

J1L 0H8

Diex Research Sherbrooke Inc., Sherbrooke

00144

Istituti Fisioterapici Ospitalieri, Istituto di Ricovero e Cura a Carattere Scientifico,, Roma

467-8602

Nagoya City University Hospital - Dermatology, Nagoya

980-8574

Tohoku University Hospital, Sendai

113-8603

Nippon Medical School Hospital, Bunkyo-ku

160-0023

Tokyo Medical University Hospital, Shinjuku-ku

400-8506

Yamanashi Prefectural Central Hospital, Kofu

03722

Severance Hospital, Yonsei University Health System, Seoul

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03715829 - A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects | Biotech Hunter | Biotech Hunter